La Jolla Institute’s signature partnership with Kyowa Kirin is the longest academic-industry collaboration in the world. Throughout the 30+ year history, the partnership has provided a mutually beneficial scientific exchange of knowledge, expertise and resources to support biomedical research, and through this exchange, a number of La Jolla Institute’s technologies have entered into Kyowa Kirin’s R&D pipeline and human clinical studies.
Clinical Development of Technologies
A number of La Jolla Institute’s discoveries around Tumor Necrosis Factors have been partnered with major pharmaceutical companies for clinical development. Some of the partnerships have been announced by press release: CD40, LIGHT (Sanofi Aventis, Medgenics) and OX40L.
Outside of the Tumor Necrosis Factor family, several technologies are in early stage, pre-clinical and clinical development through partnerships with various pharmaceutical companies.
As an academic research organization, La Jolla Institute discoveries are often nascent and require cultivation. Determination, expertise, and experience are essential to drive devices, products, and therapies into the market place, and La Jolla Institute connects with seasoned entrepreneurs and investors to help lay the foundation for new companies and commercialize technologies.